Prostate Cancer

Sarki A. Abdulkadir, MD, PhD, discusses the challenges of targeting MYC in prostate cancer.

Himisha Beltran, MD, discusses the significance of genomic sequencing in prostate cancer.

The FDA has approved the FoundationOne Liquid CDx for use as a companion diagnostic with olaparib, which is indicated for select patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer.

African American men with low-risk prostate cancer who received active surveillance had a statistically significant increased 10-year cumulative incidence of disease progression and definitive treatment compared with non-Hispanic white men.

James B. Yu, MD, MHS, discusses the utility of radiation in men with prostate cancer.

Brandon Mahal, MD, discusses the emerging role of epigenomics in prostate cancer.

The European Union has approved olaparib for use in patients with metastatic castration-resistant prostate cancer who harbor BRCA1/2 mutations.

PARP inhibitors have emerged as a promising therapeutic target in prostate cancer at the 38th Annual CFS® virtual conference.

Monica L. Baskin, PhD, discusses the roles of race and early screening in prostate cancer.

Himisha Beltran, MD, discusses the need to identify non–androgen receptor targets in prostate cancer.

Brandon Mahal, MD, assistant professor of radiation oncology, assistant director of community outreach and engagement, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the prevalence of prostate cancer among African American men. 

The FDA has lifted the clinical hold placed on the phase 1 PSMA-101-001 study of the CAR T-cell therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer.

Neal D. Shore, MD, FACS, discusses the need for further education on molecular testing for metastatic castration-resistant prostate cancer.

The use of advanced molecular imaging with the PET radiotracer fluciclovine (18F) to inform treatment decisions can lead to improved disease-free survival rates in patients with recurrent prostate cancer.

Jean-Philippe Theurillat, MD, discusses castration and androgen receptor inhibition in prostate cancer.

Daniel W. Lin, MD, discusses the role of genomic markers in prostate cancer.

Sarki A. Abdulkadir, MD, PhD, discusses the rationale to target MYC in prostate cancer.

The addition of enzalutamide to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer improved radiographic progression-free survival, regardless of baseline prostate-specific antigen levels.

Paul C. Boutros, PhD, MBA, discusses processes that predict disease lethality in men with prostate cancer.

Brandon Mahal, MD, discusses the potential role of race with regard to molecular disparities among men with prostate cancer.

Monica L. Baskin, PhD, discusses treatment considerations in prostate cancer.

Arun Azad, PhD, discusses the significance of the PROfound trial in metastatic castration-resistant prostate cancer.

Philip W. Kantoff, MD, discusses future research efforts in prostate cancer.

Neal D. Shore, MD, FACS, discusses unmet needs in nonmetastatic castration-resistant prostate cancer.

Daniel P. Petrylak, MD, discusses future research in prostate cancer.

A novel surgical technique called the “hood technique” for robotic-assisted radical prostatectomy was shown to achieve early return of urinary continence without a negative impact on complications and cancer outcomes among men with localized prostate cancer.

Ray McDermott, discusses preventing recurrence in patients with very high-risk prostate cancer.

Maha Hussain, MD, FACP, FASCO, discusses the importance of meaningful effect in prostate cancer trials.

Neal D. Shore, MD, FACS, highlights the role of darolutamide plus androgen deprivation therapy and how it continues to demonstrate a highly favorable tolerability and safety profile in patients with nonmetastatic castration-resistant prostate cancer.

The combination of onvansertib plus abiraterone acetate and prednisone achieved disease control in patients with metastatic castration-resistant prostate cancer who had initial resistance to abiraterone.